Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRÎ± kinase inhibitor for PDGFRÎ± driving chronic eosinophilic leukemia

Article ID	Journal	Published Year	Pages	File Type
7796547	European Journal of Medicinal Chemistry	2018	19 Pages	PDF

Keywords

STAT3 RTK PDGFR GISTs PARP TGI v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog ERK Cel SAR IHC Immunohistochemistry Terminal deoxynucleotidyl transferase dUTP nick end labeling intraperitoneal injection gastrointestinal stromal tumors TUNEL Structure-activity relationship NSCLC Non-small cell lung cancer Abl kinase Pharmacodynamics Pharmacokinetics Chronic eosinophilic leukemia signal transducer and activator of transcription 3 Tumor Growth Inhibition Kinase inhibitor hematoxylin-eosin extracellular regulated protein kinases poly ADP-ribose polymerase receptor tyrosine kinases Receptor Tyrosine Kinase platelet-derived growth factor receptor

Related Topics

Physical Sciences and Engineering Chemistry Organic Chemistry

Preview

Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRÎ± kinase inhibitor for PDGFRÎ± driving chronic eosinophilic leukemia

Authors

Qiang Wang, Feiyang Liu, Shuang Qi, Ziping Qi, Xiao-E. Yan, Beilei Wang, Aoli Wang, Wei Wang, Cheng Chen, Xiaochuan Liu, Zongru Jiang, Zhenquan Hu, Li Wang, Wenchao Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun, Qingsong Liu, Jing Liu,